CD274 and gastroesophageal junction adenocarcinoma: In G/GEJ adenocarcinoma, the indications for ICIs targeting the PD-1/PD-L1 pathway have gradually progressed from third-line to first-line treatment, establishing their important role in advanced systemic therapy.